In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $9.00. The company’s shares closed ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...

Sage Therapeutics (SAGE) announced that its board ... will result in any transaction or other strategic outcome. Sage does not intend to disclose further developments on this strategic review ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... result in any transaction or other strategic outcome. Sage does not intend to disclose further developments on this strategic ...

Investing.com -- Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE ... opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s ...

Sage Therapeutics has clarified that there is no definitive timeline set for the review process and no decisions have been made regarding potential strategic alternatives at this stage. The ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics ... "Sage does not intend to disclose ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...